trials—or exploratory microdosing studies—may be low-risk, but they are still subject to stringent regulatory oversight. Each country has unique pathways for approval, risk classification, and ethical review. Understanding how agencies like the FDA (U.S.), EMA (Europe), CDSCO (India), and PMDA (Japan) approach Phase 0 trials is essential for global drug development planning.

United States: FDA Exploratory IND Pathway

Key Framework

The U.S. Food and Drug Administration (FDA) introduced the Exploratory IND guidance in 2006 to enable early human testing with reduced preclinical burdens. These studies are not intended to evaluate safety or efficacy but to gather PK, PD, or imaging data.

Requirements

• Single-dose toxicity in one species (often rodent)
• Genotoxicity assessment required
• Well-defined manufacturing and formulation data for microdose
• Preclinical data presented in IND format (21 CFR Part 312)

Timelines and Review

Exploratory INDs are reviewed within 30 calendar days. If no clinical hold is issued, studies may begin. IRB approval is required concurrently.

European Union: EMA and Member State CTAs

Regulatory Approach

The European Medicines Agency (EMA) recognizes Phase 0 as exploratory first-in-human studies under the EU Clinical Trials Regulation (EU-CTR). Sponsors must file a Clinical Trial Application (CTA) to national competent authorities through the Clinical Trials Information System (CTIS).

Requirements

• ICH M3(R2) guidance followed for reduced preclinical package
• Pre-submission Scientific Advice is highly recommended
• Risk mitigation strategy must be justified in protocol
• Documentation prepared in Common Technical Document (CTD) format

Timelines

Review timelines vary by member state but typically range from 30 to 60 days. Ethics and regulatory reviews may be coordinated or separate, depending on the country.

India: CDSCO and Schedule Y Pathway

Regulatory Overview

The Central Drugs Standard Control Organization (CDSCO) allows pilot exploratory studies under Schedule Y, which aligns with ICH and WHO GCP guidelines. Studies must be registered with the CTRI (Clinical Trials Registry India) and approved by CDSCO and an Institutional Ethics Committee.

Key Documents Required

• Form CT-04: Application for permission to conduct a clinical trial
• Form CT-06: Regulatory approval document
• Preclinical data from at least one GLP-compliant species
• Details on drug formulation, batch records, and dose rationale

Timelines

Approval typically takes 60–90 days, but delays may occur if queries arise. Study registration on CTRI must be completed before first volunteer enrollment.

Japan: PMDA and Risk-Based Review

Regulatory Path

The Pharmaceuticals and Medical Devices Agency (PMDA) permits microdose trials through a risk-based approach. While no formal “Phase 0” classification exists, exploratory studies are allowed as long as they meet safety requirements and fall under the standard clinical trial framework.

Required Documentation

• Detailed protocol with risk mitigation clearly stated
• Preclinical safety in at least one species
• CMC data for microdose formulation

PMDA encourages early consultation meetings to streamline submissions.

Comparative Snapshot

Agency	Submission Type	Key Feature	Timeline
FDA (USA)	Exploratory IND	Reduced toxicology; microdosing focus	~30 days
EMA (EU)	CTA via CTIS	Scientific Advice recommended	30–60 days
CDSCO (India)	CT-04 + CT-06	Schedule Y guidance; CTRI mandatory	60–90 days
PMDA (Japan)	Clinical Trial Notification	Risk-based; early consultation advised	Varies (~30–60 days)

Best Practices for Global Submission Planning

• Engage with local regulatory consultants early in planning
• Tailor preclinical packages to each agency’s expectations
• Synchronize ethical and regulatory timelines to avoid delays
• Maintain consistency in protocol objectives across regions

Conclusion

Phase 0 trials provide a fast track to early human data, but each country requires tailored regulatory strategies. Sponsors aiming for multinational studies must navigate different terminology, documentation formats, and review mechanisms. Being proactive, well-informed, and locally engaged ensures that Phase 0 trials not only begin on time—but also deliver globally usable data.